A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage.

Sewon Kang, Gerald G. Krueger, Emil A. Tanghetti, Deborah Lew-Kaya, John Sefton, Patricia S. Walker, John R. Gibson

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Previous studies indicate that tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of tazarotene 0.1% cream in the treatment of facial photodamage. METHODS: A total of 568 patients with at least moderate fine wrinkling or mottled hyperpigmentation applied tazarotene 0.1% cream or vehicle cream to their face once daily for 24 weeks. RESULTS: Tazarotene cream was significantly more effective than vehicle in reducing fine wrinkles, mottled hyperpigmentation, lentigines, irregular depigmentation, apparent pore size, elastosis, tactile roughness, and an overall integrated assessment of photodamage. Significance was achieved as early as week 2 for some parameters and had not plateaued by week 24. The majority of patients reported improvements in their photodamage as early as week 4. Adverse events were predominantly mild or moderate signs or symptoms of skin irritation. CONCLUSION: Once-daily tazarotene 0.1% cream is effective in ameliorating multiple signs of facial photodamage.

Original languageEnglish (US)
Pages (from-to)268-274
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume52
Issue number2
StatePublished - Feb 2005
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage.'. Together they form a unique fingerprint.

  • Cite this

    Kang, S., Krueger, G. G., Tanghetti, E. A., Lew-Kaya, D., Sefton, J., Walker, P. S., & Gibson, J. R. (2005). A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. Journal of the American Academy of Dermatology, 52(2), 268-274.